RxDoctor Payments DataLook up a doctor →

Homa Porter, MD

Urology · Dallas, TXNPI 1073560058

Payments from drug & device makers

$1,803,856in general payments, 2019–2025

Across 346 payments — averaging $5213.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$856K
  • Merck$800K
  • AbbVie$79K
  • Bayer$57K
  • Astellas Pharma Global Development$6K
  • Sumitomo Pharma America, Inc.$819
  • plus $4K from 39 others
$736in research payments, 2019–2025

Across 6 payments — averaging $122.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$736

What the payments were for

  • Travel & lodging$5459%
  • Food & beverage$5,49591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,803,856 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$598,988
Medicare patients
1,043
Services billed
31,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide73$1,036,333
XtandiEnzalutamide49$670,215
OrgovyxRelugolix193$489,157
MyrbetriqMirabegron265$181,991
GemtesaVibegron82$61,180
Tamsulosin Hcl746$12,826
Mirabegron ErMirabegron23$10,355
Silodosin185$8,673
Abiraterone Acetate28$7,666
Dutasteride179$5,523
Finasteride299$4,006
Alfuzosin Hcl ErAlfuzosin Hcl155$3,478
Solifenacin Succinate91$3,207
Oxybutynin Chloride ErOxybutynin Chloride55$2,533
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst47$1,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$377$1,036,33373 claims
Astellas Pharma US IncXtandi, Myrbetriq$263$852,206314 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$819$550,337275 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.

Other urology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →